Key facts
- This page summarizes Yadin Rozov's Form 4 filing for ORAMED PHARMACEUTICALS INC. (ORMP).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 08 Jan 2024, 16:36.
Yadin Rozov - 04 Jan 2024 Form 4 Insider Report for ORAMED PHARMACEUTICALS INC. (ORMP)
- Reporting relationship
- Director
- Issuer ticker
- ORMP
- Reported as of
- 04 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Jan 2024, 16:36:18 UTC
- Prior SEC filing
- 21 Dec 2023
- Next SEC filing
- 02 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Yadin Rozov
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Yadin Rozov filed Form 4 for ORAMED PHARMACEUTICALS INC. (ORMP) on 08 Jan 2024.
Change
- Previous filing in this sequence was filed on 21 Dec 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ORMP
transaction
Common Stock
Award
- Transaction value
- Shares
- +30,000
- Change %
- +26%
- Price
- Shares after
- 146,500
- Date
- 04 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
ORMP
transaction
Common Stock
Award
- Transaction value
- Shares
- +8,820
- Change %
- +6%
- Price
- Shares after
- 155,320
- Date
- 04 Jan 2024
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 10,000 shall vest on each of January 1, 2025, January 1, 2026 and January 1, 2027. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.
Footnote F2
Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of 2,205 on April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.